middle.news
Island Pharmaceuticals Advances Galidesivir Dose Study with USAMRIID Collaboration
8:53am on Wednesday 10th of June, 2026 AEST
•
Pharmaceuticals
Read Story
Island Pharmaceuticals Advances Galidesivir Dose Study with USAMRIID Collaboration
8:53am on Wednesday 10th of June, 2026 AEST
Key Points
Expanded CRADA with USAMRIID and Geneva Foundation
Galidesivir dose optimisation study to start next quarter
Study focuses on minimally effective dose against Marburg Angola strain
Utilisation of USAMRIID’s Biosafety Level 4 containment facilities
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Island Pharmaceuticals (ASX:ILA)
OPEN ARTICLE